Smartwatches are a practical, low-cost, noninvasive method that helps in the early detection of atrial fibrillations in some patients, which increase the risk of recurrent stroke.

The head of the Rheumatology Service at Vall d'Hebron University Hospital and of the Rheumatology research group at VHIR is a highly accomplished rheumatologist with a distinguished career in the field.

It will allow the promotion of research on systemic autoimmune-based diseases that especially affect women of childbearing age and, therefore, can also appear during pregnancy.

The research has received funding from the Spanish Society of Obesity Surgery and the Spanish Association of Surgeons.

Recently, a closing meeting was organised to wrap up the first phase of the study, which aims at grouping sufficient data of patient affected by these pathologies.

Dr. Miquel Vila, head of the Neurodegenerative Diseases research group at VHIR, is the co-chair of the local organising committee. And Dr. Ariadna Laguna, principal investigator of the same group, is a scientific ambassador.

This gene therapy protects mice against cognitive deficits associated with aging, improves motor function, and delays the onset of diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.

This is the most prestigious international award in the multiple sclerosis scientific and social community, given in recognition of life-long work in care, research and teaching in relation to the disease.

Over the course of two days, experts presented the latest advances in vectors, different gene modification techniques and their transfer to clinical practice.

The finding opens the door to the development of new therapies that block neurodegeneration, beyond current treatments that focus on the inflammatory process and the control of relapses.

Vall d'Hebron professionals presented four posters, two oral communications and two lectures by Dr. Dopazo and Dr. Gomez-Gavara.

The Minister of Health, Manel Balcells, chaired the meeting of the Vall d’Hebron Research Institute (VHIR) Board of Trustees, the first of 2023.

The presentations include the one given by Dr. María Pérez Torres, who received the award for the best oral communication for a project on the use of mesenchymal cells to reduce complications after hematopoietic progenitor transplantation.

The donation will go towards two studies aimed at improving the quality of life of paediatric liver transplant patients.

Members of the Infectious Diseases research group and the VHIR Management participated in the sessions and visited the areas where the CRESCER and FUTURO projects are developed.

Dr. Simó has also recently pronounced the lecture of admission as a new member of the Royal Academy of Medicine of Catalonia.

Dr. Juan M Pericàs and Elena Sena, researchers at the Liver Diseases Group at VHIR, analyzed the impact of the socioeconomic status in the disease and the results of the EU-PEARL project on clinical trials.

The head of the Shock, Organ Dysfunction and Resuscitation group at VHIR will be part of the team that evaluates the scientific articles received by this journal, the best worldwide dedicated exclusively to intensive care medicine.

Special mention should be made of the VHIR’s participation in this study on World Prostate Cancer Day.

Dr. Vicente García-Patos received an outstanding career award and his team: a prize for the best oral communication and a first accessit for the best poster in oncology

This clinical trial is part of the RBDCOV project to test the vaccine on adolescents aged from 12 to 18.

Femtech is a spin-off of the Vall d'Hebron Research Institute (VHIR) and is part of the accelerator BCN Health Booster of the Barcelona Science Park

The end result of the initiative will be a platform that will flag risk factors and predict potential patient complications

YSOTOPE, a DeepTech start-up with the mission to improve the use of immunotherapies through medical imaging, became part of the spin-off network of VHIR and successfully closed its first investment round of €150,000 with Biozell Ventures.